TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Spironolactone Versus Prednisolone in DMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Duchenne muscular dystrophy (DMD) patients ≥4 to ≤7 years of age~* Clinical features of DMD that include proximal predominant weakness and/or gait disturbance~* Presence of a truncating mutation of the DMD gene in the patient or an affected male relative OR a muscle biopsy that demonstrates \<5% dystrophin in the patient or an affected male relative~* Normal left ventricular ejection fraction by screening echocardiogram~* Ability to cooperate for testing~* No prior treatment with glucocorticoids or vamorolone~* No concomitant experimental therapies~Exclusion Criteria:~* Subject amenable to or currently being treated with eteplirsen, casimersen, or viltolarsen~* Hyperkalemia at screening~* History of or ongoing renal failure (elevated creatinine, oliguria, anuria)~* Hypersensitivity to spironolactone (rash, respiratory distress, arrhythmia, numbness or tingling of extremities)~* Current treatment with an ACEi~* Severe peptic ulcer disease or recent gastrointestinal perforations

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Spironolactone (Type: EXPERIMENTAL): An anticipated twelve subjects will be prescribed a standard clinical dose of spironolactone of 1 mg/kg/day. The spironolactone will be provided as suspension.
- Prednisolone (Type: ACTIVE_COMPARATOR): An anticipated twelve subjects will be prescribed a standard clinical dose of prednisolone of 0.75 mg/kg/day or weekend dosing per sites standard of care. The prednisolone will be provided will be provided as suspension.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester Dilation and Evacuation Abortion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English or Spanish speaking~* Gestational age between 16 weeks 6 days and 20 weeks 6 days gestation by ultrasound dating on the day of enrollment~* Ultrasound used for dating purposes must be within the last two weeks.~* Women 18-50 years of age undergoing surgical termination of pregnancy~Exclusion Criteria:~* Spontaneous fetal demise~* Ruptured membranes or intrauterine infection~* Fibroids that significantly distort the uterine shape~* Uterine abnormality such as unicornuate uterus~* Prior transmural myomectomy~* Severe oligohydramnios~* Morbid obesity with BMI\>45~* Inability to place osmotic dilators

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Misoprostol (Type: ACTIVE_COMPARATOR): 400 mcg buccally 2 hours prior to procedure
- Placebo (Folic acid) (Type: PLACEBO_COMPARATOR): Two 1-mg tablets buccally 2 hours prior to procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prostate biopsy positive for cancer; clinically localized T1 and T2 stage disease expected, with biopsy specimen available for baseline biomarker measurements~* Scheduled for a radical prostatectomy~* Willing to sign an Institutional Review Board (IRB)-approved informed consent document and adhere to the protocol~* Willing and able to take oral medications~* Willing to refrain from drinking any kind of tea (including herbal tea) or using supplements containing green tea constituents for the duration of the study~Exclusion Criteria:~* Prior hormonal or surgical therapy for prostate cancer; including prior brachytherapy or radiation therapy~* Recent consumption of tea (six or more cups per day) or use of supplements containing green tea within one week of randomization~* Signs or symptoms of progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease~* Serum creatinine \>= 1.5 x upper limit of normal (ULN)~* Alanine aminotransferase (ALT) \>= ULN~* Aspartate aminotransferase (AST) \>= ULN~* Alkaline phosphatase (ALP) \>= ULN~* Albumin (ALB) =\< lower limit of normal (LLN)~* Total bilirubin \>= ULN~* Known malignancy at any site within the last five years; with the exception of basal cell carcinoma (BCC)~* Participation in a research trial within the past three months~* Any condition that would interfere with the ability to give informed consent or comply with the study protocol~* Hypersensitivity to tea products or any of the inactive ingredients found in the drug product capsules~* Concomitant use of at least 400 mg per day of a nonsteroidal anti-inflammatory (NSAID) agent two or more times per week

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Polyphenon E) (Type: EXPERIMENTAL): Patients receive defined green tea catechin extract PO once daily QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
- Arm II (placebo) (Type: PLACEBO_COMPARATOR): Patients receive placebo PO QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Transesophageal Echocardiography to Measure Intraoperative Renal Resistive Index and Predict Acute Renal Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* TEE is part of a anesthetic plan as determined by the anesthesiologist~Exclusion Criteria:~* Subjects on hemodialysis/peritoneal dialysis~* Subjects with a contraindication to use of TEE; esophageal stricture, esophageal diverticulum, esophageal tumor, recent esophageal/gastric surgery or radiation to the chest~* Subjects who are pregnant~* Subjects with esophageal varices~* Subjects with bleeding disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Collection of Blood Samples in Patients With Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of non-small cell lung carcinoma for which the molecular profile of the primary tumor has been obtained from a block of paraffin-embedded, formalin-fixed tissue that remains available~* Zubrod performance status 0 or 1~* Patients must have metastatic or unresectable disease and be starting a new line of systemic treatment at the time of enrollment; there are no constraints regarding the time interval between the initial collection of samples for molecular profiling studies at the time of diagnosis prior to treatment and subsequent collections of circulating cell-free deoxyribonucleic acid (DNA) or circulating tumor cells~* Patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1~* Ability to understand and the willingness to sign a written informed consent; Note: There will be no discrimination between type of treatment or whether they are on continuous versus intermittent therapy~Exclusion Criteria:~* Known severe anemia (hemoglobin \[Hb\] \< 8g/dL)~* Patients will be excluded if trackable driver mutations are not identified in the primary tumor tissue

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ancillary-Correlative (biospecimen collection) (Type: None): Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Alternative Social Assistance Disbursement on Drug-related Harm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* be ≥19 years of age or older~* reside in greater Vancouver, Canada~* report regular use of illicit drugs other than cannabis~* receive monthly provincial income assistance~* are not currently administered (where cheque issue/money is externally managed)~* be eligible and willing to be a client of the local credit union who will administer the intervention~* report intensified drug use around government cheque issue days~* provide written informed consent~* be willing to comply with study procedures~Exclusion Criteria:~* plan to relocate outside Vancouver~* have plans to discontinue income assistance

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Treatment As Usual (TAU) (Type: NO_INTERVENTION): Receipt of social assistance on government cheque issue days for 6 income assistance cycles (approx 26 weeks).
- Staggered Arm (Type: EXPERIMENTAL): Receipt of social assistance once monthly on a randomly assigned day that does not fall during the week of government cheque issue (Non-synchronized social assistance receipt), for 6 income assistance cycles (approx 26 weeks).
- Staggered and Split Arm (Type: EXPERIMENTAL): Receipt of social assistance twice monthly on equally spaced randomly assigned days that do not fall during the week of government cheque issue (Non-synchronized social assistance receipt, cheque divided into two equal disbursements), for 6 income assistance cycles (approx 26 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Transwomen, currently on treatment with estradiol therapy for at least 6 months (as their standard of care gender affirming therapy)~* Has achieved serum estradiol \>100 pg/ml at least once, based on clinical labs in past.~Exclusion Criteria:~1. Treatment with progesterone in the last 2 months~2. HIV~3. Planning to go for breast enhancement or gender reassignment surgery in the next 6 months~4. Known history of peanut allergy (because the study drug contains peanut oil)~5. Active deep vein thrombosis, pulmonary embolism or history of these conditions~6. Active arterial thromboembolic disease or history of these conditions~7. Active cardiovascular disorders or history of these conditions (e.g. myocardial infarction, uncontrolled hypertension \>150/90 mmHg)~8. Known, suspected, or history of breast cancer~9. Known liver dysfunction or disease~10. Known or history of gallbladder disease. This does not apply to subjects who have undergone cholecystectomy~11. Known or history of hypertriglyceridemia (\>400 mg/dl)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- progesterone (Type: ACTIVE_COMPARATOR): subjects on active drug (progesterone)
- placebo (Type: PLACEBO_COMPARATOR): subjects on placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with metastatic breast cancer (any site) age 21 or older~* Patients willing and able to provide informed consent \& perform study procedures~* Patients may enroll with recently (with 2 months) progressive tumor burden~* Performance status of 0,1 or 2~Exclusion Criteria:~* Patients unable or unwilling to provide informed consent and or perform study procedures~* Patients with active, uncontrolled coagulopathy~* Patients on treatment dose anticoagulation or an International Normalised Ratio of 2 or greater if on warfarin~* Patients who are known to be pregnant are not eligible to participate in this study during the time of the pregnancy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bone marrow aspirates and biopsy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Hysteroscopic Lymphatic Mapping for Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with biopsy confirmed endometrial cancer who have been dispositioned to undergo total hysterectomy, bilateral salpingooophorectomy and lymph node staging.~2. Surgical procedures may be performed by either laparotomy or laparoscopy.~3. If computed tomography, magnetic resonance imaging, lymphangiography, or ultrasound has been performed for preoperative assessment, there must be no evidence of metastases. Imaging is not mandatory.~4. Patients who have signed an approved informed consent and authorization permitting release of personal health information.~Exclusion Criteria:~1. Patients with a preoperative diagnosis of grade I endometrioid adenocarcinoma of the uterus.~2. Patients with uterine papillary serous carcinoma.~3. Patients who have undergone endometrial ablation or a myomectomy within 1 year of the surgery for endometrial cancer.~4. Patients with known allergies to triphenylmethane compounds or technetium-99 radiocolloid.~5. Patients with a history of retroperitoneal surgery.~6. Patients with a history of pelvic radiation.~7. Patients with no lesion visible on hysteroscopy.~8. Patients with previous exposure to the tracer (to prevent risk of allergic reaction).

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraoperative Lymphatic Mapping (Type: EXPERIMENTAL): Intraoperative sentinel lymph node identification (lymphatic mapping)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 18 years of age;~* Evidence of at least one donor-specific antibody (DSA);~* Recipient of a kidney transplant;~* Achieved a steady-state, post-transplant eGFR ≥ 40 mL/min/1.73 m2 within 60 days of post-transplant OR a 50% increase in urine output with a 50% decrease in serum creatinine over the first 7 days post-transplant in subjects with slow or delayed graft function;~* Acute AMR.~Exclusion Criteria:~* Recipient of an en bloc kidney transplant;~* Current active hepatitis C virus (HCV) infection;~* Active bacterial or fungal infection;~* Ongoing dialysis \>2 weeks;~* Known congenital bleeding or coagulopathy disorder;~* Current cancer or a history of cancer;~* Female subjects who are pregnant or breast feeding;~* Male or female subjects who are unwilling to use contraception or who are not surgically sterile.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C1-INH (Type: EXPERIMENTAL): C1-esterase inhibitor
- Placebo (Type: PLACEBO_COMPARATOR): Excipients of C1-INH plus albumin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Risk Factors for COVID-19 Mortality

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Admission to the Emergency Medicine Ward from the Emergency Department of Piacenza Hospital (Italy)~* Confirmed COVID-19 diagnosis through molecular test obtained from nasal-pharyngeal swabs in the Emergency Department~* Age above 18~Exclusion Criteria:~* inability to obtain an informed consent due to neurological conditions.~* patient's refusal to sign the informed consent~* inability of researchers to recruit the patient in the first 24 hours from the admission.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial : TROCC (Quick Oral Treatment of Cluster Epileptic Seizures)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age from 18 to 65~* Drug resistant epilepsy, partial seizure~* Epilepsy diagnosed for more than 2 years~* Epilepsy treated for more than 1 year with no change of treatment in the month before the enrolment~* Onset of cluster seizure in the 24 hours before enrolment~* For women : effective contraception~* Affiliation to the French social security~Exclusion Criteria:~* Inability to tolerate levetiracetam, likely poor compliance~* Patient taking antiepileptic treatment (benzodiazepine) in addition to current treatment during the last 48h00.~* Patient taking 1g/day of levetiracetam with Creatinin clearance \< 50ml/min~* Patient taking 2g/day of levetiracetam with Creatinin clearance \< 80ml/min~* Patient taking more than 2g/day of levetiracetam~* Hepatic or cardiovascular pathology~* Progressive psychiatric pathology~* Degenerative neurologic disease~* Cluster seizure due to an acute symptomatic reason~* Disorder of consciousness~* Suspicion of status epilepticus or rapid evolution to status epilepticus~* Suspicion of psychogenic nonepileptic seizure~* Pregnant woman or nursing woman~* Suicidal thoughts~* Incapacity to give consent, minor patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Perioperative Acute Renal Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients who are undergoing elective abdominal surgery after appropriate information of the study, and its possible risks that may arise therefrom and that at any time to refuse their cooperation, give a written consent to participate in the study.~* Patients who at the time of the interview have an ASA between 2 and 4.~* Patients with chronic kidney failure mild moderate (serum creatinine between 1.5 and 3.0 mg / dl) can be included.~Exclusion Criteria:~* Chronic kidney diseases with serum creatinine higher than 3.0 mg /DL~* Laparoscopic abdominal surgery~* ASA 1 and ASA 5 patients.~* Patients with cardiac insufficiency, ascites and respiratory insufficiency~* Diastolic hypertension \> 100 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Isotonic saline (Type: EXPERIMENTAL): Isotonic saline
- No treatment (Type: NO_INTERVENTION): Habitual therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical stage 2, 3A or 3B (unresectable)~* Histologic evidence of non-small cell carcinoma~* Age \> 18 years~* Karnofsky performance status 70 or greater~* No prior radiation to the chest~* No previous chemotherapy~Exclusion Criteria:~* Clinical stage 1 or 4~* Previous malignancies except for non-melanoma skin cancer unless disease free for \> 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Proton therapy with chemotherapy (Type: EXPERIMENTAL): Induction Chemotherapy - Two cycles Taxol 200mg/m2 and Carboplatin AUC6 on day 1 and day 22. Weekly chemotherapy concurrent with radiotherapy Taxol 50mg/m2 and Carboplatin AUC 2 weekly for 5 weeks.~Proton therapy - 76 Gy in 5 weeks to lung tumor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues